Nocebo effect: The other side of placebo;Efecto nocebo: La otra cara del placebo

Medicina Clinica

Volumn 122, Issue 13, 2004, Pages 511-516

  Ferreres, Jordi ^a,b   Baños, Josep Eladi ^c   Farré, Magí ^a,b  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Adverse reactions; Drug therapy; Nocebo effect; Placebo effect

Indexed keywords

CHOLECYSTOKININ; DRUG; OPIATE; PLACEBO;

CONDITIONING; HUMAN; LEARNING; MEDLINE; NEUROPHARMACOLOGY; NOCEBO EFFECT; PSYCHOPHARMACOLOGY; REVIEW; SIDE EFFECT; SOMATIZATION;

EID: 2442506665     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13060185     Document Type: Review

References (31)

1. García-Alonso F, Guallar E, Bakke OM, Carné X. El placebo en ensayos clínicos con medicamentos. Med Clin (Barc) 1997;109:797-801.
2. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622-7.
3. Lachaux B, Lemoine P. Objeto placebo, acción placebo, efecto placebo. En: Lachaux B, Lemoine P, editores. Placebo: un medicamento que busca la verdad. Madrid: McGraw-Hill-Interamericana, 1989; p. 27-83.
4. Rodríguez JL, Casado A. Doble ciego. El control de los sesgos en la realización de ensayos clínicos. Contradicciones, insuficiencias e implicaciones. Med Clin (Barc) 2002;118:192-5.
5. Baños JE, Farré M. Reacciones adversas a los medicamentos. En: Baños JE, Farré M, editores. Principios de farmacología clínica: bases científicas de la utilización de medicamentos. Barcelona: Masson, 2002; p. 69-86.
6. Papakostas YG, Daras MD. Placebos, placebo effect, and the response to the healing situation: the evolution of a concept. Epilepsia 2001;42:1614-125.
7. Emilien G, Maloteaux JM, Seghers A, Charles G. Use of a placebo in clinical trials. Eur Psychiatry 1998;13:254-63.
8. Macedo A, Farré M, Baños JE. Placebo effect and placebos: what are we talking about? Some conceptual and historical considerations. Eur J Clin Pharmacol 2003;59:337-42.
9. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment 1998. Disponible en: http://www.journals.apa.ors/prevention/volume1/pre0010002a.html
10. Guallar E, Jiménez FJ, García-Alonso F, Bakke OM. La regresión a la media en la investigación y práctica clinica. Med Clin (Barc) 1997;109:23-6.
11. Hróbjartsson A, Gotzsche PC. Is the placebo powerless?: an analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344:1594-602.
12. Rosenzweig P, Brohier S, Zipfel A. The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies. Clin Pharmacol Ther 1993;54:578-83.
13. Sibille M, Deigat N, Janin A, Kirkesseli S, Vital Durand D. Adverse events in phase-I studies: a report in 1015 healthy volunteers. Eur J Clin Pharmacol 1998;54:13-20.
14. Myers MG, Cairns JA, Singer J. The consent form as a possible cause of side effects. Clin Pharmacol Ther 1987;42:250-3.
15. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Engl J Med 1968;79:678-9.
16. Baños JE, Farré M. Efecto placebo. En: Baños JE, Farré M, editores. Principios de farmacología clínica: bases científicas de la utilización de medicamentos. Barcelona: Masson, 2002; p. 169-77.
17. Ströhle A. Increased response to a putative panicogenic nocebo administration in female patients with panic disorder. J Psychiatr Res 2000; 34:439-42.
18. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain 1990;43:121-28.
19. Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia: expectation-activated opioide systems versus conditioning-activated specific subsystems. J Neurosci 1999;19:484-94.
20. Amanzio M, Pollo A, Maggi G, Benedetti F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 2001;90:205-15.
21. Hahn RA. The nocebo phenomenon: concept, evidence, and implications for public health. Prev Med 1997;26:607-11.
22. Camí J, De la Torre R, García-Sevilla L, Ugena B, Knobel H, Segura J. Alcohol antagonism of hypercortisolism induced by naloxone. Clin Pharmacol Ther 1988;43:599-604.
23. Camí J, Guerra D, Ugena B, Segura J, De la Torre R. Effect of subject expectancy on the THC intoxication and disposition from smoked hashish cigarettes. Pharmacol Biochem Behav 1991;40:115-19.
24. Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I. Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23:4315-23.
25. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 2002;159:122-9.
26. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002;159:728-37.
27. Fuente-Fernández R De la, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-6.
28. De la Fuente-Fernández R, Thomas J, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 2001;293:1164-6.
29. Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet 1995;346:1231.
30. Benedetti F, Amanzio M, Casadio C, Oliano A, Maggi G. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain 1997;71:135-40.
31. Johansen O, Brox J, Flaten MV. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosom Med 2003;65:786-90.